Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says

Novartis CEO Vas Narasimhan stated the company will not join the weight loss drug market, focusing instead on unique areas like treatments for secondary effects of weight loss. Avoiding direct competition with major obesity drugmakers, Narasimhan highlighted Novartis’ research in reducing side effects and retaining muscle mass. The company aims to target winning areas like Alzheimer’s, Huntington’s, Parkinson’s, and cancer therapies, particularly its radioligand therapies, expecting to build a $20 billion business and maintain a distinct position in the market.

Full Article